What is the share price of SeQuent Scientific Ltd (SEQUENT) today?
The share price of SEQUENT as on 23rd June 2025 is ₹184.41. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on SeQuent Scientific Ltd (SEQUENT) share?
The past returns of SeQuent Scientific Ltd (SEQUENT) share are- Past 1 week: -4.34%
- Past 1 month: 4.87%
- Past 3 months: 27.44%
- Past 6 months: 5.16%
- Past 1 year: 56.04%
- Past 3 years: 91.10%
- Past 5 years: 98.18%
What are the peers or stocks similar to SeQuent Scientific Ltd (SEQUENT)?
The peers or stocks similar to SeQuent Scientific Ltd (SEQUENT) include:What is the market cap of SeQuent Scientific Ltd (SEQUENT) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of SeQuent Scientific Ltd (SEQUENT) is ₹4608.27 Cr as of 23rd June 2025.What is the 52 week high and low of SeQuent Scientific Ltd (SEQUENT) share?
The 52-week high of SeQuent Scientific Ltd (SEQUENT) is ₹240.70 and the 52-week low is ₹116.40.What is the PE and PB ratio of SeQuent Scientific Ltd (SEQUENT) stock?
The P/E (price-to-earnings) ratio of SeQuent Scientific Ltd (SEQUENT) is 210.62. The P/B (price-to-book) ratio is 6.46.Which sector does SeQuent Scientific Ltd (SEQUENT) belong to?
SeQuent Scientific Ltd (SEQUENT) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy SeQuent Scientific Ltd (SEQUENT) shares?
You can directly buy SeQuent Scientific Ltd (SEQUENT) shares on Tickertape. Simply sign up, connect your demat account and place your order.
SeQuent Scientific Ltd
SEQUENT Share Price
184.411.43% (-2.68)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
SEQUENT Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
SEQUENT Performance & Key Metrics
SEQUENT Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 213.68 | 6.56 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 35.51 | 6.52 | 0.85% |
SEQUENT Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
SEQUENT Company Profile
SeQuent Scientific Limited is a holding company that operates in pharmaceutical sector.
SUNPHARMA
PE Ratio
36.56
36.56
1Y Return
11.24%
11.24%
Buy Reco %
87.88
87.88
CIPLA
PE Ratio
22.97
22.97
1Y Return
0.35%
0.35%
Buy Reco %
74.19
74.19
DRREDDY
PE Ratio
19.50
19.50
1Y Return
8.83%
8.83%
Buy Reco %
56.67
56.67
TORNTPHARM
PE Ratio
56.09
56.09
1Y Return
11.44%
11.44%
Buy Reco %
72.00
72.00
ZYDUSLIFE
PE Ratio
21.28
21.28
1Y Return
12.08%
12.08%
Buy Reco %
46.43
46.43
SEQUENT Sentiment Analysis
SEQUENT Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
SEQUENT Stock Summary · May 2025
In Q4 FY25, the company achieved a remarkable turnaround, reporting a profit after tax of INR 322 million, a 208.9% increase from the previous year’s loss, driven by an 11.2% revenue growth to INR 4,017 million. The formulations business thrived with nearly 20% growth, while the API segment showed signs of recovery, bolstered by strategic initiatives and a focus on operational efficiency. Despite challenges with cash flow conversion due to high inventory levels, management remains optimistic about future growth, particularly with the upcoming merger with Viyash Life Sciences, which is expected to enhance R&D capabilities and operational performance. The company is also expanding its companion animal health segment and pursuing opportunities in the CDMO space, positioning itself for sustained growth and improved margins.
SEQUENT Stock Growth Drivers
SEQUENT Stock Growth Drivers
7Strong Financial Performance
SeQuent Scientific Limited reported robust financial results for Q4 FY '25, achieving revenues of INR
Improved Margins and Profitability
The company achieved a significant turnaround in profit after tax, moving from a loss in
SEQUENT Stock Challenges
SEQUENT Stock Challenges
5Revenue Decline
The company has experienced a 3% decline in revenue quarter-on-quarter, attributed to inventory buildup in
Limited Product Offering in Companion Animal Health
Currently, the companion animal health segment constitutes less than 10% of the company's product offerings.
SEQUENT Forecast
SEQUENT Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
SEQUENT
SEQUENT
Income
Balance Sheet
Cash Flow
Annual Normal View
SEQUENT Income Statement
SEQUENT Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 694.65 | 1,292.62 | 1,047.98 | 1,189.33 | 1,369.98 | 1,423.67 | 1,427.30 | 1,395.45 | 1,566.06 | 1,566.06 | ||||||||||
Raw Materials | 366.89 | 486.44 | 570.52 | 600.59 | 733.68 | 842.41 | 814.87 | 789.20 | 1,394.55 | 1,394.55 | ||||||||||
| Power & Fuel Cost | 12.77 | 14.66 | 23.06 | 24.73 | 28.75 | 33.86 | 42.45 | 35.46 | ||||||||||||
| Employee Cost | 106.22 | 113.83 | 145.95 | 165.06 | 187.22 | 231.37 | 258.39 | 250.57 | ||||||||||||
| Selling & Administrative Expenses | 74.68 | 94.72 | 90.93 | 108.27 | 115.85 | 132.65 | 139.02 | 138.35 | ||||||||||||
| Operating & Other expenses | 82.59 | 64.28 | 83.92 | 110.27 | 92.86 | 63.12 | 219.02 | 126.88 | ||||||||||||
EBITDA | 51.50 | 518.69 | 133.60 | 180.41 | 211.62 | 120.26 | -46.45 | 54.99 | 171.51 | 171.51 | ||||||||||
| Depreciation/Amortization | 40.07 | 41.34 | 41.92 | 50.62 | 50.60 | 51.54 | 55.69 | 61.54 | 66.45 | 66.45 | ||||||||||
| PBIT | 11.43 | 477.35 | 91.68 | 129.79 | 161.02 | 68.72 | -102.14 | -6.55 | 105.06 | 105.06 | ||||||||||
| Interest & Other Items | 28.34 | 33.07 | 32.80 | 35.71 | 24.38 | 15.77 | 35.52 | 48.09 | 60.75 | 60.75 | ||||||||||
| PBT | -16.91 | 444.28 | 58.88 | 94.08 | 136.64 | 52.95 | -137.66 | -54.64 | 44.31 | 44.31 | ||||||||||
| Taxes & Other Items | -3.08 | 22.72 | 10.22 | 24.17 | 41.19 | 11.98 | -16.50 | -18.77 | 22.43 | 22.43 | ||||||||||
| Net Income | -13.83 | 421.56 | 48.66 | 69.91 | 95.45 | 40.97 | -121.16 | -35.87 | 21.88 | 21.88 | ||||||||||
| EPS | -0.53 | 15.98 | 1.91 | 2.82 | 3.84 | 1.65 | -4.87 | -1.44 | 0.88 | 0.88 | ||||||||||
| DPS | 0.00 | 0.18 | 0.20 | 0.00 | 0.50 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.01 | 0.10 | 0.00 | 0.13 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SEQUENT Company Updates
FY 2025FY 2025
Investor Presentation
May 20PDF
Feb 11PDF
Nov 13PDF
Sep 26PDF
SEQUENT Stock Peers
SEQUENT Past Performance & Peer Comparison
SEQUENT Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation-basic on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation-basic on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| SeQuent Scientific Ltd | 213.68 | 6.56 | — |
| Sun Pharmaceutical Industries Ltd | 36.56 | 5.95 | 0.96% |
| Cipla Ltd | 22.97 | 4.52 | 1.07% |
| Dr Reddy's Laboratories Ltd | 19.50 | 3.90 | 0.61% |
SEQUENT Stock Price Comparison
Compare SEQUENT with any stock or ETFCompare SEQUENT with any stock or ETF
SEQUENT
SEQUENT Holdings
SEQUENT Shareholdings
SEQUENT Promoter Holdings Trend
SEQUENT Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
SEQUENT Institutional Holdings Trend
SEQUENT Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
SEQUENT Shareholding Pattern
SEQUENT Shareholding Pattern
SEQUENT Shareholding History
SEQUENT Shareholding History
Foreign Institutions
Mutual Funds Invested in SEQUENT
Mutual Funds Invested in SEQUENT
No mutual funds holding trends are available
Top 5 Mutual Funds holding SeQuent Scientific Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 8.9064% | Percentage of the fund’s portfolio invested in the stock 1.53% | Change in the portfolio weight of the stock over the last 3 months 0.07% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 15/112 (+2) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.5847% | Percentage of the fund’s portfolio invested in the stock 6.80% | Change in the portfolio weight of the stock over the last 3 months 1.04% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 11/27 (-1) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.3448% | Percentage of the fund’s portfolio invested in the stock 1.57% | Change in the portfolio weight of the stock over the last 3 months -0.04% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 27/45 (-2) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing SEQUENT stock
smallcases containing SEQUENT stock
Looks like this stock is not in any smallcase yet.
SEQUENT Events
SEQUENT Events
SEQUENT Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
SEQUENT Dividend Trend
No dividend trend available
SEQUENT Upcoming Dividends
SEQUENT Upcoming Dividends
No upcoming dividends are available
SEQUENT Past Dividends
SEQUENT Past Dividends
Cash Dividend
Ex DateEx DateSep 8, 2021
Final
Final | Div/Share: ₹0.50
Dividend/Share
₹0.50
Ex DateEx Date
Sep 8, 2021
Cash Dividend
Ex DateEx DateAug 21, 2019
Final
Final | Div/Share: ₹0.20
Dividend/Share
₹0.20
Ex DateEx Date
Aug 21, 2019
Cash Dividend
Ex DateEx DateNov 20, 2017
Interim
Interim | Div/Share: ₹0.20
Dividend/Share
₹0.20
Ex DateEx Date
Nov 20, 2017
Cash Dividend
Ex DateEx DateSep 16, 2011
Final
Final | Div/Share: ₹1.50
Dividend/Share
₹1.50
Ex DateEx Date
Sep 16, 2011
Cash Dividend
Ex DateEx DateSep 23, 2010
Final
Final | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Sep 23, 2010
SEQUENT Stock News & Opinions
SEQUENT Stock News & Opinions
Articles & Videos
Corporate
Sequent Scientific allots Equity shares
Sequent Scientific has approved the issue and allotment of 3,000 Equity Shares of Rs. 2/- each fully paid to one Employee at an exercise price of Rs. 86/- per equity share on exercise of the options granted to him under SeQuent ESOP 2020.Powered by Capital Market - Live
5 days agoCapital Market - Live
Earnings
Sequent Scientific reports consolidated net profit of Rs 9.32 crore in the March 2025 quarter
Net profit of Sequent Scientific reported to Rs 9.32 crore in the quarter ended March 2025 as against net loss of Rs 0.92 crore during the previous quarter ended March 2024. Sales rose 11.21% to Rs 401.70 crore in the quarter ended March 2025 as against Rs 361.20 crore during the previous quarter ended March 2024. For the full year,net profit reported to Rs 21.88 crore in the year ended March 2025 as against net loss of Rs 35.88 crore during the previous year ended March 2024. Sales rose 13.26% to Rs 1551.37 crore in the year ended March 2025 as against Rs 1369.73 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales401.70361.20 11 1551.371369.73 13 OPM %11.518.93 -10.434.48 - PBDT32.7723.83 38 115.7324.28 377 PBT16.657.35 127 49.28-37.26 LP NP9.32-0.92 LP 21.88-35.88 LP Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Sequent Scientific to hold board meeting
Sequent Scientific will hold a meeting of the Board of Directors of the Company on 20 May 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Sequent Scientific consolidated net profit declines 58.40% in the December 2024 quarter
Net profit of Sequent Scientific declined 58.40% to Rs 3.44 crore in the quarter ended December 2024 as against Rs 8.27 crore during the previous quarter ended December 2023. Sales rose 18.66% to Rs 390.81 crore in the quarter ended December 2024 as against Rs 329.36 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales390.81329.36 19 OPM %8.836.76 - PBDT25.3914.19 79 PBT8.41-1.27 LP NP3.448.27 -58 Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Sequent Scientific announces board meeting date
Sequent Scientific will hold a meeting of the Board of Directors of the Company on 11 February 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Sequent Scientific receives CCI approval for composite scheme of amalgamation
Sequent Scientific announced that the Competition Commission of India vide its letter dated 21 January 2025 has approved the composite Scheme of amalgamation amongst Sequent Scientific, Symed Labs, Vandana Life Sciences, Appcure Labs, Vindhya Pharma (India), S.V. Labs, Vindhya Organics, Viyash Life Sciences, Geninn Life Sciences and Sequent Research and their respective shareholders and the creditors. Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Sequent Scientific allots 5.40 lakh equity shares under ESOP
Sequent Scientific has allotted 5,40,000 equity shares under ESOP on 23 November 2024. With this allotment, the paid up equity share capital has increased to Rs. Rs. 50,06,03,990/-consisting of 25,03,01,995 equity shares of Rs. 2/- each.Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Sequent Scientific consolidates its holdings in N-VET AB, Sweden and Alivira Italia SRL, Italy
Sequent Scientific has completed the acquisition of 3.90% stake from Ms. Katarina Agren in N-VET AB through Alivira Animal Health, Ireland, Wholly Owned Subsidiary of the Company. The company also completed the acquisition of 3.75% stake from Renzo Rimondi and 1.25% from Ramon Vila Vina, collectively 5%, in Alivira Italia SRL, through Alivira Animal Health, Ireland, Wholly Owned Subsidiary of the Company. Consequent to the above acquisitions, N-VET AB and Alivira Italia SRL have become Wholly Owned Subsidiaries of the Company.Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Sequent Scientific announces board meeting date
Sequent Scientific will hold a meeting of the Board of Directors of the Company on 13 November 2024Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Sequent Scientific allots Equity Shares
Sequent Scientific has approved the issue and allotment of 120,000 Equity Shares of Rs. 2/- each fully paid to two Employees at an exercise price of Rs. 86/- per equity share on exercise of the options granted to them under SeQuent ESOP 2020. Powered by Capital Market - Live
7 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 5.89%, vs industry avg of 9.02%
Over the last 5 years, market share decreased from 0.48% to 0.37%